Amgen Seeks U.K. Ban On Biosimilar Interchangeability With Innovator Product
Executive Summary
Amgen has won the support of several U.K. legislators who are advocating a ban on the automatic substitution of innovator biopharmaceuticals, but it appears unlikely the British government will impose such a prohibition